Cidara Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -27 | -49 | -90,753 | -61 |
EBITDA | -27,384 | -25,220 | -54,123 | -17,333 |
EBIT | -27,411 | -25,269 | -54,182 | -17,394 |
Net Income | -25,718 | -23,480 | -52,307 | -15,535 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -40,961 | -21,950 | -29,414 | -36,801 |
Cash | 510,575 | 168,150 | 189,825 | 127,386 |
Basic Shares | 15,547 | 14,177 | 9,727 | 6,530 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $1,275 | $63,905 | $64,288 | $49,572 |
Gross Profit | -83,608 | 62,382 | 64,288 | 49,572 |
EBITDA | -176,102 | -24,365 | -28,493 | -43,485 |
EBIT | -176,335 | -24,483 | -29,718 | -42,255 |
Net Income | -169,827 | -22,931 | -29,799 | -43,909 |
Net Change In Cash | 1,275 | 63,905 | 64,288 | 49,572 |
Cost of Revenue | -29,542 | |||
Free Cash Flow | -176,662 | -22,937 | -28,591 | -25,273 |
Cash | 189,825 | 35,778 | 32,731 | 62,273 |
Basic Shares | 6,349 | 4,371 | 3,492 | 2,622 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$1.65 |
2025-03-31 | -$1.66 |
2024-12-31 | -$5.38 |
2024-09-30 | -$2.45 |
